Search

Your search keyword '"Tirri, R."' showing total 215 results
Start Over Author "Tirri, R."
215 results on '"Tirri, R."'

2. The data project: a shared approach between stakeholders of the healthcare system in definition of a therapeutic algorithm for inflammatory arthritis

Author

Pantano, I., primary, Mauro, D., additional, Simone, D., additional, Costa, L., additional, Capocotta, D., additional, Raimondo, M., additional, Birra, D., additional, Cuomo, G., additional, D'Errico, T., additional, Ferrucci, M., additional, Comentale, F., additional, Italiano, G., additional, Moscato, P., additional, Pappone, N., additional, Russo, R., additional, Scarpato, S., additional, Tirri, R., additional, Buono, P., additional, Postiglione, A., additional, Guida, R., additional, Scarpa, R., additional, Trama, U., additional, Tirri, E., additional, and Ciccia, F., additional

Published
2023
Full Text
View/download PDF

10. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study

Author

Caporali, R., Idolazzi, L., Bombardieri, S., Ferraccioli, G., Gerli, R., Govoni, M., Matucci-Cerinic, M., Pomponio, G., Salaffi, F., Tirri, R., Benaglio, F., Bianchino, L., Sarzi-Puttini, P., Adami, S., Afeltra, A., Altomonte, L., Arrigoni, E., Bagnato, G., Bianchi, G., Bucci, R. N., Caminiti, M., Cantini, F., Caputo, D., Carlino, G., Clerico, P., Colombelli, P., Corsaro, S. M., D Alessandro, G., Riso, L., Silva, S., D Errico, T., Di Matteo, L., Ferri, C., Foti, R., Fusaro, E., Gabrielli, A., Giacomelli, R., Lunardi, C., Malavolta, N., Martin Martin, L. S., Massarotti, M. S., Mazzone, A., Meschini, C., Migliore, A., Minisola, G., Monti, G., Muratore, M., Paoletti, F., Pappone, N., Passiu, G., Mario Pirisi, Pistone, G., Pozzi, M. R., Prandini, P., Provenzano, G., Ricioppo, A., Romeo, N., Russo, R., Saviola, G., Semeraro, A., Tartarelli, G., Tomietto, P., Valentini, G., Zuccaro, C., Caporali, Roberto, Idolazzi, Luca, Bombardieri, Stefano, Ferraccioli, Gianfranco, Gerli, Roberto, Govoni, Marcello, Matucci-Cerinic, Marco, Pomponio, Giovanni, Salaffi, Fausto, Tirri, Rosella, Benaglio, Francesca, Bianchino, Laura, Sarzi-Puttini, Piercarlo, Caporali, R., Adami, S., Afeltra, A., Altomonte, L., Arrigoni, E., Bagnato, G., Bianchi, G., Bombardieri, S., Bucci, R. N., Caminiti, M., Cantini, F., Caputo, D., Carlino, G., Clerico, P., Colombelli, P., Corsaro, S. M., D'Alessandro, G., De Riso, L., De Silva, S., D'Errico, T., Di Matteo, L., Ferraccioli, G., Ferri, C., Foti, R., Fusaro, E., Gabrielli, A., Gerli, R., Giacomelli, R., Govoni, M., Lunardi, C., Malavolta, N., Martin Martin, L. S., Massarotti, M. S., Matucci-Cerinic, M., Mazzone, A., Meschini, C., Migliore, A., Minisola, G., Monti, G., Muratore, M., Paoletti, F., Pappone, N., Passiu, G., Pirisi, M., Pistone, G., Pozzi, M. R., Prandini, P., Provenzano, G., Ricioppo, A., Romeo, N., Russo, R., Salaffi, F., Sarzi-Puttini, P., Saviola, G., Semeraro, A., Tartarelli, G., Tomietto, P., Valentini, G., and Zuccaro, C.

Subjects
Rheumatology, Interleukin-6, Immunology, Immunology and Allergy, Tocilizumab, Monotherapy, Rheumatoid arthriti
Abstract

Objective To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice. Methods TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion. Results 322 RA patients were enrolled in 59 Italian centres (mean age: 55.8 years; mean disease duration: 120.5 months; baseline DAS28: 5.3). After 6 months of TCZ treatment, patients achieving low disease activity (DAS28 ≤3.2; 57.52%) or disease remission (DAS28 < 2.6; 38.05%) were 216 out of 226 patients with available DAS28 (p < 0.001). No statistically significant differences were found in mean DAS28 and HAQ score changes from baseline (start of TCZ treatment) to study end between patients previously inadequately responding to disease-modifyinganti-rheumatic drugs (DMARD-IR) or to DMARDs plus tumour necrosis factor inhibitors (DMARD +TNFi-IR): both patient populations responded to TCZ. A statistically significant decrease in mean VAS Fatigue score (48.4 vs. 34.7; p=0.0025) at month 6 was observed. In patients treated with TCZ as monotherapy (32.61%), DAS28, VAS fatigue and HAQ scores decreased from baseline to any post-baseline time point. Overall, 62 patients (19.3%) prematurely discontinued TCZ treatment, 24 (7.5%) for safety reasons. Drug-related adverse events occurred in 92 patients (28.6%) (mostly 3 hypercholesterolaemia and leucopenia) and drug-related serious adverse events in 11 patients (3.4%). Conclusion This study confirms the good effectiveness and safety profile of TCZ in real life RA patient care.

Published
2017

11. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study

Author

Sarzi-Puttini, P., Bianchino, L., Francesca Benaglio, Tirri, R., Salaffi, F., Pomponio, G., Cerinic, M. Matucci, Govoni, M., Gerli, R., Ferraccioli, G., Bombardieri, S., Idolazzi, L., and Caporali, R.

Subjects
Adult, Male, rheumatoid arthritis, tocilizumab, rheumatoid arthritis, clinical practice, Tumor Necrosis Factor-alpha, TRUST study, Middle Aged, Antibodies, Monoclonal, Humanized, Tocilizumab, rheumatoid arthritis, TRUST study, Receptors, Interleukin-6, NO, clinical practice, Arthritis, Rheumatoid, tocilizumab, Antirheumatic Agents, Humans, Female, Aged
Abstract

To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice.TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion.322 RA patients were enrolled in 59 Italian centres (mean age: 55.8 years; mean disease duration: 120.5 months; baseline DAS28: 5.3). After 6 months of TCZ treatment, patients achieving low disease activity (DAS28 ≤3.2; 57.52%) or disease remission (DAS282.6; 38.05%) were 216 out of 226 patients with available DAS28 (p0.001). No statistically significant differences were found in mean DAS28 and HAQ score changes from baseline (start of TCZ treatment) to study end between patients previously inadequately responding to disease-modifyinganti-rheumatic drugs (DMARD-IR) or to DMARDs plus tumour necrosis factor inhibitors (DMARD +TNFi-IR): both patient populations responded to TCZ. A statistically significant decrease in mean VAS Fatigue score (48.4 vs. 34.7; p=0.0025) at month 6 was observed. In patients treated with TCZ as monotherapy (32.61%), DAS28, VAS fatigue and HAQ scores decreased from baseline to any post-baseline time point. Overall, 62 patients (19.3%) prematurely discontinued TCZ treatment, 24 (7.5%) for safety reasons. Drug-related adverse events occurred in 92 patients (28.6%) (mostly 3 hypercholesterolaemia and leucopenia) and drug-related serious adverse events in 11 patients (3.4%).This study confirms the good effectiveness and safety profile of TCZ in real life RA patient care.

Published
2017

13. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet Database

Author

Scire', C, Caporali, R, Sarzi Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salaffi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C, Todesco, S, SCIRE', Carlo Alberto, Caporali R, Sarzi Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, GOVONI, Marcello, Gerli R, Raschetti R, Minisola G, Montecucco C, Todesco S., Scire', C, Caporali, R, Sarzi Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salaffi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C, Todesco, S, SCIRE', Carlo Alberto, Caporali R, Sarzi Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, GOVONI, Marcello, Gerli R, Raschetti R, Minisola G, Montecucco C, and Todesco S.

Abstract

Objective: To compare drug survival of different anti-TNF drugs (inliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicentre observational cohort study.Methods: All patients with RA or SpA registered in the MonitorNet database who started their irst course of anti-TNF therapy were included.Overall drug survival was measured, along with speciic reasons of discontinuation (ineficacy or adverse events).A first set of analyses using RA as reference category assessed the relationship between diagnosis and drug survival.A second set of analyses stratiied by diagnosis (RA and SpA) used INF as reference drug.Adjustment for confounders was performed.The results are presented as adjusted hazard ratios (adjHR) and 95% conidence intervals (95%CI).Results: 2640 RA patients and 1220 SpA patients with a median follow-up of 17 months (IQR 7.2-33.4) were included in the analyses.Patients with a diagnosis of SpA showed a lower risk of drug discontinuation with an adjHR (95%CI) of 0.81 (0.73, 0.90).In SpA, the subset of patients with ankylosing spondylitis (AS) showed the best survival on treatment.In RA, both ETA and ADA showed a signiicantly lower probability of withdrawal when compared to INF [adjHR (95%CI) 0.46 (0.38, 0.56) and 0.68 (0.57, 0.81), respectively].Similar results were found in SpA.Conclusion: Drug survival for SpA is longer than that in RA mainly due to the AS subgroup.In both RA and SpA, ETA and ADA showed a better retention on treatment when compared to INF.

Published
2013

15. OP0015 Induction of remission and maintenance in early, aggressive rheumatoid arthritis using adalimumab in combination with methotrexate with or without short-term high-dose glucocorticoids: results of a phase iv multicenter, randomized, double blind study (clintrial.gov: NCT00480272)

Author

Caporali, R, primary, Montecucco, C, additional, Bocci, E Bartoloni, additional, Vitolo, B, additional, Prisco, E, additional, Klersy, C, additional, Giacomelli, R, additional, Triolo, G, additional, Cutolo, M, additional, Marchesoni, A, additional, Gremese, E, additional, Iannuccelli, C, additional, Tirri, R, additional, Grassi, W, additional, Lopalco, G, additional, Galeazzi, M, additional, Cerinic, M Matucci, additional, Punzi, L, additional, and Ferraccioli, G, additional

Published
2017
Full Text
View/download PDF

18. Mediterranean Symposium of rheumatology: Naples, 14–15 June, 1984

Author

Schiavetti, L., Galeazzi, M., Purpura, M., Pras, M., Zemer, D., Cabili, S., Ciocci, A., Colombo, B., Tosi, S., Govoni, E., Genacchi, G., Carcassi, U., Mela, Q., Bonomo, L., Aiuti, F., D'Amelio, R., Puigdollers-Colas, J. M., Roca-Rossellini, N., Permanyer-Barrier, J., Rovellat, M. A. Puigdollers, Georgiadis, A. E., Yazici, H., Tuzun, Y., Yurdakul, S., Pazarli, H., Ozyazgan, Y., Ozdogan, H., Serdarogu, S., Ersanli, M., Ulku, B., Muftuoglu, A., Dilsen, N., Konice, M., Aral, O., Giordano, M., Cotticelli, L., Migliaresi, S., Picillo, U., Tirri, G., Hamza, M., Ciompi, M. L., Fosella, P. V., Ammannati, P., Gremignal, G., Olivieri, I., Tassoni, S., Pecori, F., Gamici, M., Porciatt, A., Fantini, F., Valenti, F., Marin, F., Mercuriali, F., Figueirinhas, J., Silva, V., Tanakol, R., Pecar, J., Daneo, V., Modena, V., Maiocco, I., Bosio, C., De Filipi, P. G., Drosos, A. A., Moutsopoulos, H. M., Oriente, P., Scarpa, R., Pucino, A., Biondi-Oriente, C., Jacquot, P., Blanc, M., Giordano, D., Pennec, Y., Youinou, P., Mottier, D., Jouquan, J., Gentric, A., Ferec, C., Le Menn, G., Ambamelli, U., Kontomerkos, A., Karagiannidis, N., Georgiadis, A., Dantis, P., Dilsen, G., Rovetta, G., Cervini, C., Hadidi, T., Valentini, G., Chianese, U., Gualdieri, L., Maniera, A., Tirri, R., La Palombara, F., Mavridis, A. K., Serratrice, G., Schiano, A., Desnuelles, C., Pouget, J., Zoppini, A., Taccari, E., Teddori, S., Roux, H., Antipoff, G. M., Paris, D., Thivolet, J., Hermier, C., Fabiano, F., Bevilacqua, M., Ramonda, R., Lazzarin, P., Ostuni, P. A., Todesco, S., Contantopoulos, S. H., Capelli, L., Vatti, M., Fichera, G., Sany, J., Combes, B., Cosso, B., Bonneaux, M., Andary, M., Clot, J., Consoli, G., Di Mattteo, L., Wirth, W., Lonauer, G., Demptroeder, F., Sinigaglia, L., Guidi, G., Ranza, R., Marchesoni, A., Abdelkafi, M. M., Medeb, T., Kassab, M. T., Cammoun, M., Jaafoura, H., Hamza, R., Ben Lamine, B., Traballi, G., Aletti, A., Imbimbo, B., Canesi, B. A., Cutolo, M., Accardo, S., Castellani, P., Borsi, L., Cimmino, M., Zardi, L., Scagliusi, P., Fasiello, V., De Lucia, M., Loizzi, P., Pipitone, V., Ribatti, D., Contino, R., Di Pietro, F., Scarano, R., Tursi, A., Le Goff, P., Coutois, B., Lydyard, P. M., Le Poivre, B., Brousse, A., Rossi, A., Bini, M., Arcidiacono, R., Canesi, B., Casadei, G., Barberis, M., Buffrini, G. Rovetta, Nicolini, F., Zakraoui, L., Daly, L., Daouissi, N., Haddad, S., La Montagna, G., Gallo, M., Squame, G., Giordano, A., Quattrocchi, G., Molica, A., Grasso, E., Lagana, A., Sirna, R., Olivieri, J., Rizzo, G., Porciatti, A., Italia, A., Capone, M., Zorbin, L., Cherie-Ligniere, G., Marconi, A., Colombo, B., Coche, P., Riccio, A., De Marco, F., Farinaro, C., Prantera, T., Ferri, S., Villeco, A. S., Giacovazzo, M., Romiti, A., Martelletti, P., Gallo, M. F., Casale, R., Sessarego, P., Kokodoko, A., Dato, G., Cimmino, M. A., Bianchi, G., Mancinelli, S., Marazzi, M. C., Palombi, L., Concerva, P., Fiore, L., Biaccarini, V., Pana, A., Venegoni, C., Chevallard, M., Carrabba, M., Paresce, E., Anelini, M., Viara, M., Galcagno, L., Mercier, P., Fasciolo, D., Maglio, M. L., Carrara, P., Seriolo, B., Ferretti, A., Giglio, A., Vinci, M., Raciti, T., Gatto, A., DiStefano, F., Carcassi, A., Boschi, S., Campagna, S., Quattrohi, G., Musolino, C., Aliquo, E., Di Stefano, F., Crovato, F., Nazzari, G., Herne, J. P., Cledes, J., Guillodo, M. P., Le Guy, P., Bourbigot, B., Riccio, R., Farinaro, L., Scognamiglio, A., Lanteri, L., Percivalle, A., Maccagolo, P., Soave, G., Samanta, E., Zorzin, L., and Biagiotti, T.

Published
1985
Full Text
View/download PDF

20. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

Author

Giacomelli, R, Gorla, R, Trotta, F, Tirri, R, Grassi, W, Bazzichi, L, Galeazzi, M, Matucci Cerinic, M, Scarpa, R, Cantini, F, Gerli, R, Lapadula, G, Sinigaglia, L, Ferraccioli, Gianfranco, Olivieri, I, Ruscitti, P, Sarzi Puttini, P., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Giacomelli, R, Gorla, R, Trotta, F, Tirri, R, Grassi, W, Bazzichi, L, Galeazzi, M, Matucci Cerinic, M, Scarpa, R, Cantini, F, Gerli, R, Lapadula, G, Sinigaglia, L, Ferraccioli, Gianfranco, Olivieri, I, Ruscitti, P, Sarzi Puttini, P., and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

Abstract

The observational RAPSODIA (RA, PsA and spondylitis including AS) study was planned to assess, in patients with RA, AS and PsA, their involvement in medical decisions, quality of life and unmet needs 15 years after the introduction of biologic therapies in Italy.

Published
2015

24. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

Author

Giacomelli, R, Gorla, R, Trotta, F, Tirri, R, Grassi, W, Bazzichi, L, Galeazzi, M, Matucci Cerinic, M, Scarpa, R, Cantini, F, Gerli, R, Lapadula, G, Sinigaglia, L, Ferraccioli, Gianfranco, Olivieri, I, Ruscitti, P, Sarzi Puttini, P., Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Giacomelli, R, Gorla, R, Trotta, F, Tirri, R, Grassi, W, Bazzichi, L, Galeazzi, M, Matucci Cerinic, M, Scarpa, R, Cantini, F, Gerli, R, Lapadula, G, Sinigaglia, L, Ferraccioli, Gianfranco, Olivieri, I, Ruscitti, P, Sarzi Puttini, P., and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

Abstract

The observational RAPSODIA (RA, PsA and spondylitis including AS) study was planned to assess, in patients with RA, AS and PsA, their involvement in medical decisions, quality of life and unmet needs 15 years after the introduction of biologic therapies in Italy.

Published
2014

27. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study

Author

Giacomelli, R., primary, Gorla, R., additional, Trotta, F., additional, Tirri, R., additional, Grassi, W., additional, Bazzichi, L., additional, Galeazzi, M., additional, Matucci-Cerinic, M., additional, Scarpa, R., additional, Cantini, F., additional, Gerli, R., additional, Lapadula, G., additional, Sinigaglia, L., additional, Ferraccioli, G., additional, Olivieri, I., additional, Ruscitti, P., additional, and Sarzi-Puttini, P., additional

Published
2014
Full Text
View/download PDF

28. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

Author

Scirè, Ca, Caporali, R, Sarzi Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salaffi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C, Todesco, S, Ferraccioli, Gianfranco, Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428), Scirè, Ca, Caporali, R, Sarzi Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salaffi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C, Todesco, S, Ferraccioli, Gianfranco, and Ferraccioli, Gianfranco (ORCID:0000-0001-6246-2428)

Abstract

To compare drug survival of different anti-TNF drugs (infliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicenter observational cohort study.

Published
2013

31. Evidence for bone resorption in systemic sclerosis

Author

La Montagna G, Baruffo A, Salvatore ABBADESSA, Maja L, Tirri R, LA MONTAGNA, G, Baruffo, A, Abbadessa, Salvatore, Maja, L, and Tirri, Rosella

Subjects
Adult, Male, Scleroderma, Systemic, Creatinine, Humans, Female, Pyridinium Compounds, Bone Resorption, Middle Aged
Published
1995

45. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: Analysis from the monitornet databas

Author

Scirè, Ca, Caporali, R, Sarzi Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salaffi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C, Todesco, S, Naldi, L, Galeazzi, M, Fantini, F, Mathieu, A, Valesini, G, Ferri, Clodoveo, Bambara, Lm, Grassi, W, Trotta, F, Adami, S, Lapadula, G, Pellerito, R, De Vita, S, Foti, R, Paolazzi, G, Bagnato, G, Cutolo, M, Rocchetta, Pa, Ferraccioli, G, Canesi, Ba, Matucci Cerinic, M, Vittorio, M, Canzoni, M., Scire', C, Caporali, R, Sarzi Puttini, P, Frediani, B, Di Franco, M, Tincani, A, Sinigaglia, L, Sfriso, P, Tirri, R, Bellis, E, Delsante, G, Porru, G, Salaffi, F, Giuggioli, D, Rossini, M, Todoerti, M, Bazzichi, L, Govoni, M, Gerli, R, Raschetti, R, Minisola, G, Montecucco, C, Todesco, S, Scirè, Ca, SARZI PUTTINI, P, DI FRANCO, M, Tirri, Rosella, and Todesco, S.

Subjects
rheumatoid arthritis, Adult, Male, Settore MED/16 - REUMATOLOGIA, Time Factors, Databases, Factual, databases, retention rate, Anti-TNFalpha blockers, Kaplan-Meier Estimate, Drug Administration Schedule, NO, anti-TNF, Rheumatoid arthritis, seronegative spondyloarthritis, Arthritis, Rheumatoid, Databases, anti-TNF therapies, Risk Factors, Rheumatoid, Spondylarthritis, Humans, Registries, Treatment Failure, Rheumatoid arthriti, Factual, Aged, Proportional Hazards Models, therapy, Tumor Necrosis Factor-alpha, Arthritis, seronegative spondyloarthriti, Middle Aged, Italy, Antirheumatic Agents, Multivariate Analysis, Female, Biomarkers
Abstract

Objective: To compare drug survival of different anti-TNF drugs (inliximab, INF, etanercept, ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by analysing data collected from an Italian multicentre observational cohort study.Methods: All patients with RA or SpA registered in the MonitorNet database who started their irst course of anti-TNF therapy were included.Overall drug survival was measured, along with speciic reasons of discontinuation (ineficacy or adverse events).A first set of analyses using RA as reference category assessed the relationship between diagnosis and drug survival.A second set of analyses stratiied by diagnosis (RA and SpA) used INF as reference drug.Adjustment for confounders was performed.The results are presented as adjusted hazard ratios (adjHR) and 95% conidence intervals (95%CI).Results: 2640 RA patients and 1220 SpA patients with a median follow-up of 17 months (IQR 7.2-33.4) were included in the analyses.Patients with a diagnosis of SpA showed a lower risk of drug discontinuation with an adjHR (95%CI) of 0.81 (0.73, 0.90).In SpA, the subset of patients with ankylosing spondylitis (AS) showed the best survival on treatment.In RA, both ETA and ADA showed a signiicantly lower probability of withdrawal when compared to INF [adjHR (95%CI) 0.46 (0.38, 0.56) and 0.68 (0.57, 0.81), respectively].Similar results were found in SpA.Conclusion: Drug survival for SpA is longer than that in RA mainly due to the AS subgroup.In both RA and SpA, ETA and ADA showed a better retention on treatment when compared to INF.

46. SOME ASPECTS OF THE FUNCTION OF FSH- AND LH-LIKE HORMONES IN NORMAL AND HYPOPHYSECTOMIZED FEMALE RATS, IN CONNECTION WITH RESERPINE ADMINISTRATION

Author

Grönroos, M., Mäkinen, E., Lahtinen, K., and Tirri, R.

Abstract

The effect of reserpine on the secretion of FSH and LH was studied as well as the role of the peripheral effect of reserpine after hypophysectomy.The results in the unoperated animals suggest that reserpine inhibits the pituitary secretion of both FSH and LH. Both these hormones combined with reserpine had a very different biological effect than was seen without reserpine. HCG (LH-like) and particularly PMS (FSH-like) hormones combined with reserpine caused definite enlargement of the ovaries.In the hypophysectomized groups, the effect of the PMS and HCG hormones administered together with reserpine or without it was the same with regard to the weight of the ovaries, but not with regard to their histological picture. On the basis of these results, reserpine may be said to have a peripheral effect although the nature of its mechanism of action is difficult to state. Reserpine probably affects the ovaries by inhibiting the follicular cycle and, consequently, the formation of new and more mature follicles.

Published
1965
Full Text
View/download PDF

48. SOME ASPECTS OF THE FUNCTION OF FSH- AND LH-LIKE HORMONES IN NORMAL AND HYPOPHYSECTOMIZED FEMALE RATS, IN CONNECTION WITH RESERPINE ADMINISTRATION

Author

Tirri R, Maekinen E, Groenroos M, and Lahtinen K

Subjects
endocrine system, medicine.medical_specialty, Hypophysectomy, Histology, Reserpine, Physiology, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Ovary, Biology, Endocrinology, Internal medicine, medicine, Humans, Organ weight, Pharmacology, Research, General Medicine, Organ Size, Luteinizing Hormone, Rats, medicine.anatomical_structure, Female, Follicle Stimulating Hormone, Hormone, medicine.drug
Abstract

The effect of reserpine on the secretion of FSH and LH was studied as well as the role of the peripheral effect of reserpine after hypophysectomy. The results in the unoperated animals suggest that reserpine inhibits the pituitary secretion of both FSH and LH. Both these hormones combined with reserpine had a very different biological effect than was seen without reserpine. HCG (LH-like) and particularly PMS (FSH-like) hormones combined with reserpine caused definite enlargement of the ovaries. In the hypophysectomized groups, the effect of the PMS and HCG hormones administered together with reserpine or without it was the same with regard to the weight of the ovaries, but not with regard to their histological picture. On the basis of these results, reserpine may be said to have a peripheral effect although the nature of its mechanism of action is difficult to state. Reserpine probably affects the ovaries by inhibiting the follicular cycle and, consequently, the formation of new and more mature follicles.

Published
1965

49. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study

Author

Caporali, R., Idolazzi, L., Bombardieri, S., Ferraccioli, G., Gerli, R., Govoni, M., Matucci-Cerinic, M., Pomponio, G., Fausto SALAFFI, Tirri, R., Benaglio, F., Bianchino, L., Sarzi-Puttini, P., Adami, S., Afeltra, A., Altomonte, L., Arrigoni, E., Bagnato, G., Bianchi, G., Bucci, R. N., Caminiti, M., Cantini, F., Caputo, D., Carlino, G., Clerico, P., Colombelli, P., Corsaro, S. M., D Alessandro, G., Riso, L., Silva, S., D Errico, T., Di Matteo, L., Ferri, C., Foti, R., Fusaro, E., Gabrielli, A., Giacomelli, R., Lunardi, C., Malavolta, N., Martin Martin, L. S., Massarotti, M. S., Mazzone, A., Meschini, C., Migliore, A., Minisola, G., Monti, G., Muratore, M., Paoletti, F., Pappone, N., Passiu, G., Pirisi, M., Pistone, G., Pozzi, M. R., Prandini, P., Provenzano, G., Ricioppo, A., Romeo, N., Russo, R., Saviola, G., Semeraro, A., Tartarelli, G., Tomietto, P., Valentini, G., and Zuccaro, C.

50. Epidemiology and risk factors in osteoarthritis: Literature review data from 'OASIS' study | Epidemiologia e fattori di rischio dell'osteoartrosi: Review della letteratura e dati dal progetto OASIS

Author

Filippis, L., Gulli, S., Caliri, A., Claudio Romano, Munaò, F., Trimarchi, G., La Torre, D., Fichera, C., Pappalardo, A., Triolo, G., Gallo, M., Valentini, G., Bagnato, G., Acampora, R., Accardi, A., Arrigo, C., Barbagallo, M., Barbuto, G., Bartolone, S., Bocchino, L., Califano, E., Candiote, G., Carpinelli, A., Chirico, G., Ciccia, F., Cuzzucoli, M., Corsaro, S. M., D Avola, G., Gaetano, P., Grasso, E., Silva, S., Di Girolamo, C., Di Paola, A., Di Stefano, R., Farina, G., Ferrante, A., Foti, R., Galfo, G., Italiano, G., Iuliano, P., La Trecchia, A., Lo Gullo, R., Lordi, G., Mantova, D., Manzo, C., Marino, F., Miceli, G., Molica, C. A., Montaruli, M., Morgante, L., Muccari, G., Muratore, A., Nutile, G., Peruz, G. G., Pinelli, P., Pistone, G., Pucino, A., Quattrocchi, E., Raffa, G., Russo, R., Sambataro, A., Sangari, D., Scarpato, S., Scibilia, G., Scognamiglio, A., Spanò, A., Spataro, M., Stisi, S., Tirri, R., Toriello, G., Torre, R., Tropea, S., and Varcasia, G.

Catalog

Books, media, physical & digital resources
See catalog results